NAMUR, Belgium, Feb. 24, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has just acquired the unencumbered assignment of the patent family WO 2005/019826 originally filed by Chroma Therapeutics Limited, a UK-based biotechnology company. VolitionRx's rights to this patent were previously held through a world-wide exclusive licensing agreement. Following this assignment, VolitionRx directly owns all core Nucleosomics® patents with no royalties or other encumbrances.
The WO 2005/019826 patent family relates to developments, made by scientists working at Chroma Therapeutics Limited, in the detection of chemically modified chromosome fragments, called nucleosomes, from cancer cells circulating in the blood of cancer patients. The scientists were able to show that cancer could be detected by measuring nucleosomes containing chemically modified histone proteins in a simple blood test.
Cameron Reynolds, Chief Executive Officer of VolitionRx, remarked, "The acquisition of this patent further strengthens VolitionRx's market and IP position in this exciting platform technology, maximizing the value of our Nucleosomics® platform for the company. Having all the core Nucleosomics IP completely royalty free is a very positive outcome for the retention of the value we aim to create for our shareholders."
Dr. Jake Micallef, Chief Scientific Officer of VolitionRx, commented, "We congratulate Chroma Therapeutics Limited for their pioneering work. Scientists working at VolitionRx have developed further innovative Nucleosomics® methods and tests for a wide variety of chromatin fragment structures to continuously expand our patent portfolio, which currently stands at 10 families of granted patents and pending applications."
Recent VNRX News
- Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech • PR Newswire (US) • 04/23/2024 12:00:00 PM
- U.S. Index Futures on the Rise, Oil Prices Show Stability • IH Market News • 03/26/2024 11:21:42 AM
- VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update • PR Newswire (US) • 03/25/2024 08:10:00 PM
- VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update • PR Newswire (US) • 03/21/2024 12:30:00 PM
- Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan • PR Newswire (US) • 03/20/2024 12:30:00 PM
- Volition appoints Dr Andrew Retter as Chief Medical Officer • PR Newswire (US) • 03/19/2024 08:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:45 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/09/2024 08:56:57 PM
- Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:05:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:05:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:05:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:04:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:04:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:04:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:04:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:04:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:03:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:03:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:02:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:02:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:02:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:01:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:01:38 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM